x

Portfolio

AUSZUG AUS DEM PORTFOLIO

Altavo

Altavo is a Dresden-based Medtech start-up with the vision of improving the reha­bili­tation and quality of life of people without a voice. Based on a combi­nation of AI algo­rithms and non-invasive radar sensor techno­logy, the company is deve­loping an arti­ficial voice that sets new standards in terms of voice quality and user-friendli­ness. The first field of appli­cation is cancer patients who have lost their voice after laryn­gectomy.

Chipmetrics

Chipmetrics sets a new standard by developing and manu­facturing innovative metrology chips and wafers for the semiconductor industry. The Finnish company is the leading expert in con­formality measure­ments of thin films using 3D high aspect ratio test elements. Appli­cations are in thin film process develop­ment, tool quali­fication and quality assurance in semi­conductor and advanced materials manu­facturing – a rapidly growing and evolving industry.

ReCatalyst

ReCatalyst is a Slovenian spin-off company of the National Institute of Chemistry in Ljubljana, developing innovative catalysts for fuel cells. The company is building a ground­breaking nano­technology platform for the production of cutting-edge (electro)catalysts for fuel cells and water electrolyzers with the mission to optimize the use of platinum group metals. The company is dedicated to accelerating the decarbonization of the energy and transport sectors.

EBAMed

EBAMed is a Geneva-based medical device company active in the ambitious field of proton therapy. The company is developing a novel treat­ment system to monitor and react to heart movement during cardiac radioablation proce­dures. The aim is to reduce the volume of healthy heart exposed to more than 20 gray of protons/photons during cardiac radio ablation, thereby maxi­mizing long-term safety for patients.

core sensing

core sensing from Darmstadt develops an innovative sensor technology that uses smart sensors inside mechanical components in combination with intelligent algorithms to provide valuable insights into machines, plants and commercial vehicles. This allows them to be digitized and thus operated more efficiently, potential problems to be detected at an early stage, expensive scrap and downtime costs to be avoided, and new digital business models to be implemented.

avelo

Avelo is a Zurich-based diagnostics startup developing a simple breath collector to improve the diagnosis of tuberculosis and other respiratory infections that cause pneumonia – the fourth leading cause of death worldwide. The breath collector will enable non-invasive and painless samples, particularly from the lower respiratory tract, which can be analyzed with existing PCR testing infrastructure.

mk2 Biotechnologies

mk2 is a Munich-based biotechnology company specializing in the development, production and research of peptides. The basis for this is a revolutionary technology platform, which enables the scalable and thus cost-effective synthesis of peptides of the highest quality and purity. With the help of this tech­nology, authentic peptides with any physical and chemical properties can be synthesized.

hemotune

hemotune is developing a unique approach to extracorporeal blood purification. The HemoSystem platform technology uses magnetic nanoparticles to selectively remove previously inaccessible biomolecules from the blood. Initially, the method is to be used primarily in cases of an uncontrolled immune reaction (septic shock). In addition, the platform can also be used for a variety of other indications.

Tubulis

Tubulis uses proprietary technologies to develop novel drugs whose mechanisms of operation address the deep-seated causes of the respective disease. The goal is to expand the therapeutic potential of Antibody Drug Conjugates (ADCs) to enable more targeted and effective treatment of cancer and other diseases.

Code Intelligence

Code Intelligence enables software security testing through innovative fuzzing already in the development phase. Using CI Fuzz, vulner­abilities can be detected earlier and fully automatically, so that developers can analyze bugs faster and fix them at the code base. CI Fuzz thus drastically improves software stability and reliability.

Algiax Pharmaceuticals

Algiax Pharmaceuticals researches and develops innovative products for the treatment of diseases with high unmet medical demand. The core of the development is AP-325, a low-molecular GABAA receptor modulator, which is currently in clinical development as a therapy for neuropathic pain.

Thermosome

Thermosome is a clinical-stage drug development company focused on targeted tumor therapy with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin being developed in soft tissue sarcoma.

iThera

iThera Medical develops optoacoustic imaging systems for preclinical research and clinical diagnostics. Optoacoustics uses the photo­acoustic effect – absorption of laser light in tissue generates an ultrasound signal – the analysis of which, without invasive intervention, provides information on a wide range of indications, such as cancer or inflammatory diseases.

Resistell

Resistell is developing a technology for quicker, more precise antibiotic susceptibility testing. After bacteria have been exposed to antibiotics, their effect can be demonstrated by the changing movement of bacterial cells. In comparison to a culture-based antibiogram, this method provides results within a few hours. This allows patients to receive the right medication in the right concentration, from day one.

Implandata

Implandata Ophthalmic Products (IOP) designs, produces and distributes disruptive solutions for ophthalmology, particularly for glaucoma patients. The CE-approved eyemate® system combines state-of-the-art medical technology with digital health solutions and therefore enables more efficient therapy and disease management.

advanceCOR

advanceCOR develops innovative medications for the treatment of cardio­vascular diseases. At the heart of this research and development is Revacept®, a therapeutic agent in clinical development for the treatment of acute arterial thromboses and thromboembolism.

4tiitoo

4tiitoo develops a framework for Natural User Interfaces (NUIA), which can be used in all applications and which allows controlling the computer using eyes, gestures and speech. As a result, workplaces can be designed more productively and employees can accomplish their tasks more efficiently, safely and with fewer ergonomic restrictions.

Insphero

InSphero offers advanced yet easy-to-use tissue-based 3D assay solutions for predictive drug classification to bring more reliable, effective drugs to the market faster. The core of the solution are the physiologically relevant 3D InSight™ platforms and associated microchip technologies.

iMusician

iMusician provides copyright services to musicians around the world. The company monetizes copyrights, organizes digital distribution, handles license fees and also offers mastering of tracks for tens of thousands of musicians.

EXITS

adivo

EXIT

adivo developed a technology platform for the selection of species-specific thera­peutic anti­bodies for veterinary medicine. These anti­bodies had predefined characte­ristics that enabled the generation of lead candidates with optimal functio­nality for dogs and other animals. After the ongoing colla­boration in canine antibody drug discovery since 2021, which was expanded to include adivo’s novel feline antibody library in 2022, the exit to Zoetis Inc. (NYSE:ZTS), the global leader in animal health, took place in 2023.

Lunaphore

EXIT

Lunaphore was developing an immuno­histo­chemical testing procedure that uses micro­fluidic systems to achieve faster, more precise analysis of tumor tissue. In addition, Lunaphore enabled digital pathology by inte­grating imaging systems such as a micro­scope with sequential data extraction. Lunaphore was acquired by the global life sciences company Bio-Techne Corporation (NASDAQ:TECH) in 2023.

Versantis

EXIT

Versantis developed drugs and diagnostics for the treatment of acute and chronic liver failure with the aim of revolutionizing previous standards of care. The lead project VS-01 was in pre-clinical phase 2 at exit with the potential to become a first-line therapy for chronic liver failure. Versantis was acquired by GENFIT in September 2022 to jointly continue the develop­ment of its revolutionary therapeutics.

GNA Biosolutions

EXIT

GNA Biosolutions developed a disruptive PCA (Pulse Controlled Amplification) technology for DNA analysis from complex clinical samples. GNA’s technology delivers results within a few minutes and is therefore significantly faster and cheaper than other solutions in the field of mole­cular diagnostics. GNA’s rapid tests are also used for the diagnosis of COVID-19.

Cunesoft

EXIT

cunesoft developed an innovative software platform for the pharma­ceutical industry’s regulatory processes, which leads to more efficient processes and thus to easier and faster drug approval. In early 2020, the company exited to Phlexglobal, a leading provider of technologies and services in the clinical and regulatory area.

Kooaba

EXIT

kooaba developed an augmented reality technology platform for image recognition on mobile devices. By enriching it with additional information about the identified object, an exciting combination of the physical world with digital content is created. In 2014, kooaba was acquired by Qualcomm, one of the world’s largest semiconductor manufacturers and suppliers of products for mobile communications.

GET
IN
TOUCH

team@occident.ventures

Meet us here!